Clinical considerations in premenopausal osteoporosis

被引:55
作者
Gourlay, ML
Brown, SA
机构
[1] Univ N Carolina, Robert Wood Johnson Clin Scholars Program, Dept Family Med, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Dept Internal Med, Div Endocrinol, Chapel Hill, NC 27599 USA
关键词
D O I
10.1001/archinte.164.6.603
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Osteoporosis can occur at any age. In premenopausal osteoporosis, full achievement of peak bone mass may be curtailed, and accelerated bone loss may occur in young adulthood. Premenopausal osteoporosis may be associated with chronic glucocorticoid therapy, prolonged amenorrhea, anorexia nervosa, rheumatoid arthritis, and diseases that affect calcium and vitamin D metabolism. Lesser degrees of bone loss may be associated with common conditions such as dieting, low calcium intake, smoking, and oligomenorrhea. Owing to a paucity of prospective studies on screening and treatment in younger age groups, few practice recommendations exist to guide the management of osteoporosis in young adults. We review the most important clinical concerns in premenopausal osteoporosis, including measurement of bone mass, normal bone accrual, risk factors for premature bone loss, clinical outcomes, and management issues. We emphasize clinically relevant information for primary care physicians, who are usually the first to encounter premenopausal patients with risk factors for early bone loss.
引用
收藏
页码:603 / 614
页数:12
相关论文
共 138 条
  • [81] Estrogen receptor gene polymorphism and bone mineral density at the lumbar spine of pre- and postmenopausal women
    Mizunuma, H
    Hosoi, T
    Okano, H
    Soda, M
    Tokizawa, T
    Kagami, I
    Miyamoto, S
    Ibuki, Y
    Inoue, S
    Shiraki, M
    Ouchi, Y
    [J]. BONE, 1997, 21 (05) : 379 - 383
  • [82] Moreira Kulak C A, 2000, Endocr Pract, V6, P296
  • [83] DIFFERENTIAL-EFFECTS ON BONE-DENSITY OF PROGESTOGEN-ONLY METHODS FOR CONTRACEPTION IN PREMENOPAUSAL WOMEN
    NAESSEN, T
    OLSSON, SE
    GUDMUNDSON, J
    [J]. CONTRACEPTION, 1995, 52 (01) : 35 - 39
  • [84] National Osteoporosis Foundation, PHYS GUID PREV TREAT
  • [85] TYPE OF FALL AND RISK OF HIP AND WRIST FRACTURES - THE STUDY OF OSTEOPOROTIC FRACTURES
    NEVITT, MC
    CUMMINGS, SR
    BLACK, D
    GENANT, HK
    ARNAUD, C
    BROWNER, W
    FAULKER, K
    FOX, C
    GLUER, C
    HARVEY, S
    HULLEY, SB
    PALERMO, L
    SEELEY, D
    STEIGER, P
    JERGAS, M
    SHERWIN, R
    SCOTT, J
    FOX, K
    LEWIS, J
    BAHR, M
    TRUSTY, S
    HOHMAN, B
    EMERSON, L
    REBAR, D
    OLINER, E
    ENSRUD, K
    GRIMM, R
    BELL, C
    THOMAS, D
    JACOBSON, K
    JACKSON, S
    MITSON, E
    STOCKE, L
    FRANK, P
    CAULEY, JA
    KULLER, LH
    HARPER, L
    NASIM, M
    BASHADA, C
    BUCK, L
    GITHENS, A
    MEDVE, D
    RUDOVSKY, S
    VOGT, TM
    VOLLMER, VM
    GLAUBER, H
    ORWOLL, E
    BLANK, J
    MASTELSMITH, B
    BRIGHT, R
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1993, 41 (11) : 1226 - 1234
  • [86] *NIH NAT LIB MED, POWER STUD BON LOSS
  • [87] Adolescent screening for orthopedic problems in high school
    Nussinovitch, M
    Finkelstein, Y
    Amir, J
    Greenbaum, E
    Volovitz, B
    [J]. PUBLIC HEALTH, 2002, 116 (01) : 30 - 32
  • [88] Estrogen receptor gene polymorphism is associated with bone mineral density in premenopausal women but not in postmenopausal women
    Ongphiphadhanakul, B
    Rajatanavin, R
    Chanprasertyothin, S
    Piaseu, N
    Chailurkit, L
    Sirisriro, R
    Komindr, S
    [J]. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1998, 21 (08) : 487 - 493
  • [89] Raloxifene administration in women treated with gonadotropin-releasing hormone agonist for uterine leiomyomas: Effects on bone metabolism
    Palomba, S
    Orio, F
    Morelli, M
    Russo, T
    Pellicano, M
    Nappi, C
    Mastrantonio, P
    Lombardi, G
    Colao, A
    Zullo, F
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (10) : 4476 - 4481
  • [90] Patlas N, 1999, TERATOLOGY, V60, P68, DOI 10.1002/(SICI)1096-9926(199908)60:2<68::AID-TERA10>3.3.CO